Back to search

Article

Lifelong genetically lowered sclerostin and risk of cardiovascular disease

2019-02-01

Abstract excerpt

<h4>Background</h4> Inhibition of sclerostin is a novel therapeutic approach to lowering fracture risk. However, phase III randomised controlled trials (RCTs) of romosozumab, a monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events. <h4>Methods</h4> We used two independent genetic variants (rs7209826 and rs188810925) in SOST (encoding sclerostin) associated with bone...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9ee672a5-9f59-560c-b043-c162a7c0b707
DOI
10.1101/531004
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Lifelong genetically lowered sclerostin and risk of cardiovascular diseaseDOI 10.1101/531004
Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.Semantic proximity
The cause-effect relationship between sclerostin levels, cardiovascular biomarkers, risk factors, and cardiovascular diseaseSemantic proximity
Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomizationSemantic proximity
Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.Semantic proximity
Sclerostin and Cardiovascular DiseaseSemantic proximity
Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.Semantic proximity
Role of Sclerostin in Cardiovascular SystemSemantic proximity
Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in HumansSemantic proximity
A novel and efficient machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibitionSemantic proximity
A flexible machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibition.Semantic proximity
B4GALNT3 regulates glycosylation of sclerostin and bone massSemantic proximity
Cardio-metabolic-related plasma proteins reveal biological links between cardiovascular diseases and fragility fractures: a cohort and Mendelian randomisation investigationSemantic proximity
Select a neighboring publication to make it the new centre.